NEW NUMBER OF SHARES AND VOTES IN KARO BIO AB (PUBL)

NEW NUMBER OF SHARES AND VOTES IN KARO BIO AB (PUBL)

STOCKHOLM, December 30, 2009. Karo Bio AB (publ) (Reuters: KARO.ST) today
announced that the company's total number of shares as per December 30, 2009
amounts to 154,825,589 shares, corresponding to an equal number of votes. The
increase in the number of shares and votes results from an issue of 38,706,397
shares under Karo Bio's rights issue that was announced on October 26, 2009.



For more information please contact:
Per Olof Wallström, President
Tel: +46 8 608 60 20
E-mail: p.o.wallstrom@karobio.se

Erika Söderberg Johnson, CFO and responsible for Investor Relations
Tel: +46 8 608 60 52
E-mail: erika.soderberg.johnson@karobio.se



About Karo Bio
Karo Bio is a drug discovery and development company specializing in
endocrinology and targeting nuclear receptors as target proteins for the
development of novel pharmaceuticals. The company has a project portfolio with
innovative molecules that primarily target dyslipidemia, CNS-disorders,
inflammation, and women's health. In these areas, there are significant market
opportunities and a clear need for pharmaceuticals with new mechanisms of
action. Karo Bio develops compounds aimed at treating broad patient populations
up to clinical proof of concept before out-licensing. In therapeutic niche
areas, Karo Bio has the capacity to bring selected compounds into late stage
clinical development and, potentially, to the market. In addition to the
proprietary projects, Karo Bio has three strategic collaborations with
international pharmaceutical companies for development of innovative therapies
for the treatment of common diseases. Karo Bio is listed on NASDAQ OMX Stockholm
since 1998 (Reuters: KARO.ST).

Karo Bio publishes this information in accordance with the Swedish Securities
Markets Act and/or the Swedish Financial Instruments Trading Act. The
information was published on December 30, 2009 at 8:30 am CET.

This press release is also available online at: www.karobio.com and
www.newsroom.cision.com